Nio Inc – ADR (NYSE: NIO), China’s leading premium intelligent electric vehicles manufacturer, announced that Ms. Yu Long was appointed as an independent director to the firm’s board of directors on July 12, 2021. Moreover, Ms. Long will also be a member and chairperson of the board’s corporate and nominating governance committee. In contrast, the firm’s founder, CEO of the Board, and chairperson, Mr. William Bin Li, will quit the nominating and corporate authority of the firm immediately.
William Bin Li said that they are glad to welcome Ms. Long to NIO. Her brilliant record of investing in internet and tech firms will bring a unique standpoint to the firm with incredible insights into client products and global markets. In addition, they dedicate themselves to developing technology and holistic experience.
He also adds that Ms. Long will share their vision of creating a user enterprise, and they have complete faith that she will provide substantial value to the firm. Moreover, William Bin Li is looking forward to working with Ms. Long to achieve their mission of shaping a pleasant lifestyle for their users.
Clovis Oncology Appoints Dr. Ronit Simantov to its Board of Directors
Clovis Oncology Inc (NASDAQ: CLVS) declared the appointment of Dr. Ronit Simantov to its Board of Directors yesterday.
Since July 2017, Dr. Simantov has administered as chief medical officer of Gamida Cell. Previously, joining Gamida Cell, she administered as vice president, where she was accountable for multiple oncology programs in several roles in Oncology Global Medical Affairs from 2011 to June 2017.
President and CEO of Clovis Oncology Patrick J. Mahaffy said that he is delighted to welcome Dr. Simantov to their Board of Directors, as she gives rise to a wealth of aptitude in oncology research as well as drug advancement to the role. Her substantial background and knowledge will assist Clovis’ major strategic priorities as they proceed to progress both Rubraca’s pipeline into a potentially broader label and the firm’s early level pipeline of targeted radiotherapy aspirants, along with FAP-2286, into clinical improvement.